{"meta":{"query_hash":"2c75919a263e","filters":{"venue":"EJC Skin Cancer"},"cohort_total":13,"direct_labels_cover":0,"predictions_cover":13,"exported":13,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/2c75919a263e","api":"https://metacan.xera.ac/api/v1/cohort?venue=EJC+Skin+Cancer"},"results":[{"id":"W4391649234","doi":"10.1016/j.ejcskn.2024.100022","title":"Quality of life issues faced by patients with keratinocyte cancer: A systematic review","year":2024,"lang":"en","type":"review","venue":"EJC Skin Cancer","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Organisation for Research and Treatment of Cancer","keywords":"Quality of life (healthcare); Medicine; Systematic review; Distress; Modalities; MEDLINE; Gerontology; Disease; Pathology; Clinical psychology; Nursing","score_opus":0.05195869532728559,"score_gpt":0.4177770245737574,"score_spread":0.36581832924647184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391649234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017642215,0.98850584,0.0000036116826,0.00044087457,0.0007203335,0.0077086934,0.0020701713,0.00008141294,0.0004513933],"genre_scores_gemma":[0.000023714934,0.9871326,0.00008449536,0.00066259044,0.00038507758,0.007055546,0.00024930213,0.00020377962,0.004202865],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9943303,0.00043260248,0.0024693746,0.0009904044,0.0012756037,0.00050171657],"domain_scores_gemma":[0.9960499,0.00023349636,0.0018382822,0.001180316,0.00045748742,0.00024051736],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005442787,0.0010436536,0.0101416465,0.00016403144,0.00007369176,0.000035251138,0.00039035123,0.0002759952,0.0005339183],"category_scores_gemma":[0.00034721568,0.00062132213,0.0008416405,0.0008564681,0.00018407633,0.000074468815,0.00018604701,0.0006476872,0.000100097895],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034190954,0.00007846567,0.00044368752,0.8658185,0.0035893382,0.000006361485,0.00012319964,9.541036e-8,5.0975473e-8,0.000007447964,0.09976905,0.030129595],"study_design_scores_gemma":[0.000469533,0.00009727969,0.000079338766,0.5733545,0.010268301,0.000002918825,0.000011114013,2.1784375e-7,0.0000014148834,0.0000010809831,0.41531464,0.00039966637],"about_ca_topic_score_codex":0.0014109462,"about_ca_topic_score_gemma":0.00027776582,"teacher_disagreement_score":0.31554562,"about_ca_system_score_codex":0.0011028533,"about_ca_system_score_gemma":0.0015666198,"threshold_uncertainty_score":0.99962384},"labels":[],"label_agreement":null},{"id":"W4399122510","doi":"10.1016/j.ejcskn.2024.100248","title":"Survival Outcomes in T3N0 versus N1 in Head and Neck Cutaneous Squamous Cell Carcinoma – Implications for Neoadjuvant Immune Checkpoint Inhibitor Immunotherapy","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Head and neck; Immunotherapy; Oncology; Head and neck squamous-cell carcinoma; Basal cell; Immune checkpoint; Complete response; Internal medicine; Radiation therapy; Head and neck cancer; Chemotherapy; Cancer; Surgery","score_opus":0.02633942168190365,"score_gpt":0.3271439383847343,"score_spread":0.30080451670283065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94203234,0.046548426,0.00002832696,0.0067062853,0.0020194557,0.0012470324,0.00016832116,0.000065164,0.001184622],"genre_scores_gemma":[0.9955447,0.0013651242,0.00045293735,0.00015928585,0.00041022353,0.0010431351,0.000024377272,0.0000935924,0.00090665196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799013,0.00003665245,0.0006090864,0.0006234596,0.00019815647,0.0005424989],"domain_scores_gemma":[0.99879926,0.00052212813,0.00008298716,0.0004377955,0.00006575472,0.00009207362],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019064949,0.00034661437,0.00073894823,0.0002740885,0.000083936946,0.000048005204,0.00013509234,0.00013957871,0.000081602026],"category_scores_gemma":[0.00005746738,0.00031084256,0.00017880273,0.000395628,0.00011832469,0.00008956729,0.00008699323,0.00033688036,0.000011299051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035067026,0.0004912651,0.92323065,0.0009421314,0.00020933112,0.00030354084,0.00538573,0.000066698325,0.013828082,0.0003167987,0.0014217212,0.05029735],"study_design_scores_gemma":[0.010079333,0.0006743549,0.965671,0.000259741,0.0000706948,0.0000532742,0.00036846404,0.00017019818,0.006300784,0.00016363124,0.015788142,0.00040037784],"about_ca_topic_score_codex":0.0041157957,"about_ca_topic_score_gemma":0.0062616835,"teacher_disagreement_score":0.053512305,"about_ca_system_score_codex":0.0009202458,"about_ca_system_score_gemma":0.0003378709,"threshold_uncertainty_score":0.9999344},"labels":[],"label_agreement":null},{"id":"W4399122701","doi":"10.1016/j.ejcskn.2024.100143","title":"A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Nivolumab; Medicine; Pharmacokinetics; Safety profile; Metastatic melanoma; Melanoma; Oncology; Pharmacology; Internal medicine; Anesthesia; Adverse effect; Cancer; Immunotherapy; Cancer research","score_opus":0.026175707076226656,"score_gpt":0.35289931568384625,"score_spread":0.3267236086076196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907767,0.0037417714,0.000013528901,0.00032702117,0.00017723569,0.003828067,0.00009758585,0.000039674538,0.0009983763],"genre_scores_gemma":[0.99240106,0.0011505112,0.00004414492,0.000020915772,0.0000424457,0.0001403111,0.000025364869,0.000056018627,0.0061192447],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99753386,0.00043288773,0.00061531307,0.00041358717,0.00064354524,0.0003608315],"domain_scores_gemma":[0.9984207,0.00075743825,0.00015464118,0.00040815887,0.00016594934,0.00009310001],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060422736,0.00023686815,0.00064097956,0.00029492725,0.00006263816,0.000026855707,0.0001780083,0.00007939409,0.0021129597],"category_scores_gemma":[0.00018564674,0.00016305604,0.0000838958,0.0012906551,0.00017890104,0.00007536758,0.00012522169,0.00053399743,0.0000053308886],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09090069,0.034466177,0.01834104,0.005805597,0.0040346934,0.0038711557,0.053476084,0.0010790746,0.123730764,0.0002374191,0.0024646968,0.6615926],"study_design_scores_gemma":[0.35004714,0.12244941,0.09860052,0.009587429,0.007848847,0.0033790143,0.0068143425,0.1774182,0.20553239,0.00053116994,0.015551661,0.0022398797],"about_ca_topic_score_codex":0.0018281956,"about_ca_topic_score_gemma":0.0012488702,"teacher_disagreement_score":0.6593527,"about_ca_system_score_codex":0.0003520616,"about_ca_system_score_gemma":0.00052924716,"threshold_uncertainty_score":0.99879926},"labels":[],"label_agreement":null},{"id":"W4399122791","doi":"10.1016/j.ejcskn.2024.100087","title":"Estimating Occupational Exposure to Ultraviolet Radiation Using the Canadian Occupation Exposure Matrix (CANJEM) in a Nationwide Cohort of French Adults","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Air Quality and Health Impacts","field":"Environmental Science","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Occupational exposure; Ultraviolet radiation; Job-exposure matrix; Radiation exposure; Environmental health; Cohort; Medicine; Environmental science; Nuclear medicine; Radiochemistry; Chemistry; Pathology","score_opus":0.02546508462888969,"score_gpt":0.3471180471206083,"score_spread":0.3216529624917186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99364644,0.00031865356,0.0023718544,0.0020489453,0.00049822463,0.00060159736,0.00016150594,0.000019168392,0.0003335846],"genre_scores_gemma":[0.9939015,0.000011862617,0.004779092,0.00092938676,0.00019415046,0.000056540845,0.00004460975,0.000012801692,0.00007007743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854606,0.00009792363,0.000378396,0.00025941624,0.0004381829,0.0002799992],"domain_scores_gemma":[0.9994463,0.00011902694,0.00009727721,0.00015585669,0.000027504439,0.00015407872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000713005,0.000114641036,0.00012449361,0.00013280413,0.00018476129,0.00005124411,0.00013900927,0.00009550035,0.00079060363],"category_scores_gemma":[0.00016851058,0.000098626435,0.000032061776,0.0006405123,0.000051799496,0.00024841167,0.000022107086,0.00016892087,0.000041492876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021802602,0.000014368658,0.7712137,0.000056209406,0.000007817849,0.0000029009218,0.006613498,0.19144137,0.0001240194,0.00009192912,0.0037356191,0.026676757],"study_design_scores_gemma":[0.00015847574,0.000038357804,0.9174976,0.00021999847,0.000010074238,0.0000028319496,0.000086179025,0.08000341,0.0001806696,0.00011024025,0.001577995,0.00011420383],"about_ca_topic_score_codex":0.5576191,"about_ca_topic_score_gemma":0.6878778,"teacher_disagreement_score":0.14628385,"about_ca_system_score_codex":0.001314032,"about_ca_system_score_gemma":0.0005544627,"threshold_uncertainty_score":0.8656555},"labels":[],"label_agreement":null},{"id":"W4399128155","doi":"10.1016/j.ejcskn.2024.100072","title":"ANALYSIS OF GLOBAL Skin-Cancer Epidemiology and Correlation with Dermatologist Density and Population Risk Factors","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Future Earth","funders":"","keywords":"Epidemiology; Skin cancer; Dermatology; Medicine; Correlation; Demography; Cancer; Internal medicine; Mathematics","score_opus":0.01726049559795837,"score_gpt":0.3143669913361692,"score_spread":0.2971064957382108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399128155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919492,0.0030102837,0.003763446,0.000578159,0.00029255607,0.00018447124,0.000042375614,0.000042894157,0.00013661094],"genre_scores_gemma":[0.99853325,0.00093996414,0.00014136762,0.00011937131,0.00004822769,0.000013591998,0.000031583386,0.00000651276,0.00016613508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992525,0.00006403844,0.00020794827,0.0002624914,0.000095999574,0.00011704593],"domain_scores_gemma":[0.99955726,0.00011943533,0.000113531234,0.00010895243,0.000037943555,0.0000628787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013251079,0.0001055728,0.0003545797,0.000114867544,0.00005272935,0.000009556051,0.000016520964,0.000075697375,0.00013585004],"category_scores_gemma":[0.000048053003,0.00007715272,0.000056942998,0.00037978776,0.00008167553,0.000040215975,0.000021550766,0.00009117328,0.0000012666925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010975285,0.000010983643,0.98022693,0.00008562131,0.00092947204,0.000012039012,0.0001366422,0.0015596383,0.0000069108905,0.00030455363,0.00034463234,0.016272807],"study_design_scores_gemma":[0.00022905784,0.000057628517,0.966723,0.000058365393,0.0023480658,0.00003324517,0.00008828895,0.028635584,0.000041914773,0.00009653628,0.0016112179,0.000077099015],"about_ca_topic_score_codex":0.01006973,"about_ca_topic_score_gemma":0.009031552,"teacher_disagreement_score":0.027075944,"about_ca_system_score_codex":0.00016380148,"about_ca_system_score_gemma":0.000025704434,"threshold_uncertainty_score":0.9965223},"labels":[],"label_agreement":null},{"id":"W4402731446","doi":"10.1016/j.ejcskn.2024.100267","title":"Sonidegib reduced tumor burden in patients with advanced basal cell carcinoma in the BOLT trial: Long-term analysis results","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Sun Pharma","keywords":"Basal cell carcinoma; Term (time); Medicine; Oncology; Internal medicine; Basal cell; Physics","score_opus":0.010212480374670724,"score_gpt":0.2700852698998302,"score_spread":0.2598727895251595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402731446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583334,0.002620408,0.000012516074,0.00028833695,0.00026143782,0.0005311203,0.00009363994,0.000011062777,0.00034816138],"genre_scores_gemma":[0.9988034,0.00007531148,0.00004405821,0.00014881472,0.0003205718,0.00022598071,0.00013861262,0.000030036794,0.00021323215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983605,0.00013319652,0.0003354678,0.0005989198,0.0002431414,0.0003287432],"domain_scores_gemma":[0.9993388,0.00004896042,0.00008137956,0.0004260654,0.000064864245,0.000039941802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032380645,0.00021263135,0.00026962697,0.00016121271,0.00004674978,0.00004672251,0.00025814323,0.00007818017,0.0000112838],"category_scores_gemma":[0.00006392287,0.0001477551,0.00011539213,0.0007058079,0.00006167296,0.0000065769223,0.000070912174,0.00017395972,0.000004179441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056485552,0.0010343697,0.8301613,0.00043372618,0.0016292221,0.0006330865,0.012814874,0.01626879,0.05303991,0.000011713306,0.010343288,0.017144186],"study_design_scores_gemma":[0.023512287,0.0010105565,0.90768373,0.00015526901,0.00029009438,8.3546615e-7,0.00032838236,0.00014144399,0.06374958,0.0000070506776,0.0025764292,0.00054432487],"about_ca_topic_score_codex":0.00034107838,"about_ca_topic_score_gemma":0.001912543,"teacher_disagreement_score":0.077522464,"about_ca_system_score_codex":0.0000832654,"about_ca_system_score_gemma":0.00017712219,"threshold_uncertainty_score":0.6025278},"labels":[],"label_agreement":null},{"id":"W4403712090","doi":"10.1016/j.ejcskn.2024.100274","title":"Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanoma","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Melanoma Institute Australia; Dartmouth Cancer Center; York University; Dartmouth College; Huntsman Cancer Institute; National Cancer Institute; Cleveland Clinic; Memorial Sloan-Kettering Cancer Center; University of North Carolina at Chapel Hill; National Institutes of Health; Yale University","keywords":"Stage (stratigraphy); Melanoma; Medicine; Disease; Overall survival; Internal medicine; Oncology; Mutation; Cancer research; Biology; Genetics; Gene","score_opus":0.006024202446509326,"score_gpt":0.20858190153793518,"score_spread":0.20255769909142585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403712090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969275,0.00045593956,0.00012655262,0.0010133953,0.00044002157,0.00059511105,0.00004693448,0.000083761726,0.00031080004],"genre_scores_gemma":[0.99612814,0.00006599706,0.00012589672,0.00015172557,0.00024513088,0.00009358452,0.000053683438,0.00004477693,0.0030910715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998873,0.000025138077,0.000168854,0.00038242343,0.0003402608,0.00021030198],"domain_scores_gemma":[0.9995799,0.00003376413,0.00004529001,0.00017055142,0.000048568458,0.00012194584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000672161,0.00017809134,0.00021032398,0.00017808758,0.00007252943,0.000055685294,0.000038923507,0.0000342264,0.00066799927],"category_scores_gemma":[0.000004480513,0.0001303668,0.000027514237,0.00024129986,0.000068210735,0.00009742744,0.00003695334,0.00017939809,0.000023701381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011514613,0.0003927939,0.8917208,0.0007984547,0.00088941574,0.0036186867,0.006227303,0.0012935163,0.00018506357,0.00043835535,0.006458506,0.07646253],"study_design_scores_gemma":[0.006627628,0.0013993036,0.90148073,0.0008750818,0.00029875262,0.000027435643,0.00064554386,0.00091158174,0.00023188005,0.000039710478,0.087014094,0.0004482283],"about_ca_topic_score_codex":0.00036114018,"about_ca_topic_score_gemma":0.00028947875,"teacher_disagreement_score":0.08055559,"about_ca_system_score_codex":0.0001986434,"about_ca_system_score_gemma":0.00005775824,"threshold_uncertainty_score":0.73141235},"labels":[],"label_agreement":null},{"id":"W4407240950","doi":"10.1016/j.ejcskn.2025.100284","title":"Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Medicine; Placebo; Internal medicine; Type 2 diabetes; Cancer; Oncology; Body mass index; Index (typography); Diabetes mellitus; Alternative medicine; Pathology; Endocrinology; Immunotherapy; Computer science","score_opus":0.03411272885735226,"score_gpt":0.36545527000434735,"score_spread":0.3313425411469951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407240950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911839,0.0054420554,0.0000061962273,0.0002138168,0.00014472117,0.0026121112,0.0002515467,0.000004729582,0.00014093259],"genre_scores_gemma":[0.9943203,0.005145538,0.000018398427,0.000010788002,0.00007451814,0.00029079372,0.00002965102,0.000015064154,0.00009500197],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986244,0.0002629916,0.0004138317,0.0002704363,0.00022844966,0.00019991027],"domain_scores_gemma":[0.99867284,0.00075318775,0.00020720666,0.00019227904,0.00014432434,0.000030162932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007888112,0.00013154176,0.00038749087,0.00023010618,0.00004694987,0.000009711947,0.00006671017,0.000071788905,0.000031196727],"category_scores_gemma":[0.00015930225,0.000094324736,0.000026568732,0.00043659584,0.0002878711,0.000048711794,0.000024394714,0.000120584584,2.305391e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5122072,0.00048038998,0.45105946,0.00026115202,0.00044591466,0.0000059020185,0.0030151797,0.0000090067115,0.0133942105,0.00002595236,0.00012356596,0.018972028],"study_design_scores_gemma":[0.3212743,0.009606963,0.6453196,0.0004162713,0.00020122735,3.3260804e-7,0.0012796103,0.0006832901,0.020747863,0.000078204306,0.00029374575,0.000098588775],"about_ca_topic_score_codex":0.004411623,"about_ca_topic_score_gemma":0.004476662,"teacher_disagreement_score":0.19426012,"about_ca_system_score_codex":0.00024675895,"about_ca_system_score_gemma":0.00036096558,"threshold_uncertainty_score":0.6669083},"labels":[],"label_agreement":null},{"id":"W4409143650","doi":"10.1016/j.ejcskn.2025.100656","title":"Overall survival in patients with metastatic uveal melanoma (MUM) treated with local therapy modality and tebentafusp in a real-world setting","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Melanoma; Modality (human–computer interaction); Medicine; Metastatic melanoma; Treatment modality; Oncology; Internal medicine; Cancer research; Computer science; Artificial intelligence","score_opus":0.011760803675786916,"score_gpt":0.299756122073091,"score_spread":0.2879953183973041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409143650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965912,0.0002617186,0.00002542409,0.0005199063,0.000042659387,0.0006964277,0.000021960535,0.000019950696,0.0018207716],"genre_scores_gemma":[0.99866205,0.00007999989,0.00023327598,0.00031439262,0.000012976853,0.00011291542,0.000053974152,0.000016946795,0.0005134792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988816,0.00013776642,0.00020987059,0.00033481524,0.00017635926,0.0002595907],"domain_scores_gemma":[0.9995839,0.00007729696,0.000066585395,0.00017017413,0.00004276432,0.000059277747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014257258,0.0001920094,0.00043499097,0.00018110432,0.000036932557,0.000009245159,0.00003866791,0.000055313893,0.000059774524],"category_scores_gemma":[0.000006137284,0.00012764033,0.000024418083,0.00037376527,0.000102967635,0.0000690396,0.000018966673,0.00018534933,0.0000012102105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037603949,0.000577321,0.9750841,0.000039159604,0.0003453669,0.00016462784,0.0002595047,0.000059194484,0.000004013013,0.00006782395,0.000027153046,0.01961129],"study_design_scores_gemma":[0.021527588,0.000605588,0.9766777,0.00028171123,0.0001116201,0.000001769798,0.000057837617,0.00019415963,0.00021382576,0.000078969504,0.00013410399,0.00011508554],"about_ca_topic_score_codex":0.011842003,"about_ca_topic_score_gemma":0.03638308,"teacher_disagreement_score":0.024541078,"about_ca_system_score_codex":0.00047041752,"about_ca_system_score_gemma":0.00022292112,"threshold_uncertainty_score":0.9947382},"labels":[],"label_agreement":null},{"id":"W4409143683","doi":"10.1016/j.ejcskn.2025.100681","title":"Once in a blue moon: A rare, metastatic malignant blue nevus","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Tellabs (Canada)","funders":"","keywords":"Blue nevus; Dermatology; Medicine; Melanoma; Nevus; Cancer research","score_opus":0.0157537423049103,"score_gpt":0.2996006327630199,"score_spread":0.2838468904581096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409143683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954091,0.0048085945,0.0028132002,0.008261046,0.0020467944,0.0014981539,0.000016421136,0.000170894,0.026293902],"genre_scores_gemma":[0.9503857,0.00038993338,0.00064276863,0.003744433,0.00012203169,0.00018574837,0.0000048531037,0.00001882361,0.044505738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99897105,0.000040348554,0.0002572315,0.00029501072,0.00018326152,0.0002530977],"domain_scores_gemma":[0.9995138,0.000046798894,0.000050247643,0.00028158433,0.000038522725,0.000069050584],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001349247,0.00013971089,0.00028365097,0.00024619454,0.000040847535,0.000021313288,0.000080364836,0.0000397565,0.0010320713],"category_scores_gemma":[0.000045376997,0.00012379453,0.00007614062,0.00051118934,0.000032655636,0.000034016637,0.000057128655,0.0001623699,0.00007488832],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033062662,0.0017182821,0.012162766,0.0028677161,0.0019898538,0.010496028,0.010556587,0.00644923,0.016159644,0.0097028725,0.15084584,0.77374494],"study_design_scores_gemma":[0.0061904374,0.0003009482,0.020619795,0.0016736847,0.00046645646,0.00029532655,0.0024701587,0.004610093,0.020153895,0.00043056838,0.9423085,0.00048016573],"about_ca_topic_score_codex":0.0012806976,"about_ca_topic_score_gemma":0.0018515849,"teacher_disagreement_score":0.79146266,"about_ca_system_score_codex":0.00032741192,"about_ca_system_score_gemma":0.00016998812,"threshold_uncertainty_score":0.99988115},"labels":[],"label_agreement":null},{"id":"W4409144909","doi":"10.1016/j.ejcskn.2025.100586","title":"A Phase 3 trial of fixed-dose combination of fianlimab + cemiplimab vs relatlimab + nivolumab in patients with unresectable or metastatic melanoma","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Nivolumab; Medicine; Oncology; Melanoma; Internal medicine; Phase (matter); Metastatic melanoma; Radiology; Cancer research; Immunotherapy; Cancer; Physics","score_opus":0.01461065501911946,"score_gpt":0.3161808704942925,"score_spread":0.30157021547517304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409144909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953731,0.00090195733,0.00005052413,0.0004029711,0.00034500938,0.0015640196,0.00011213481,0.000016734184,0.0012335572],"genre_scores_gemma":[0.99761164,0.0001720433,0.00027370607,0.00015501653,0.00002253813,0.00018199738,0.000071298375,0.000023645613,0.0014881069],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983095,0.00008806966,0.0006250029,0.00028577188,0.00043940573,0.0002522364],"domain_scores_gemma":[0.99891907,0.00015729167,0.0003117111,0.0003608894,0.00021023827,0.000040798004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030256915,0.00018937892,0.00063683034,0.0003538756,0.000037393744,0.00000993798,0.00013526775,0.00008450796,0.0005231688],"category_scores_gemma":[0.000099466066,0.00014115393,0.00011202696,0.0010046231,0.00013031159,0.0001207782,0.000033582444,0.00016811724,0.0000012821523],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.914375,0.008241073,0.025925254,0.0006999059,0.0007816792,0.000016349628,0.00078660337,0.000016226857,0.0011097743,0.00007950501,0.002396537,0.045572106],"study_design_scores_gemma":[0.8661351,0.01687494,0.093892924,0.0019276697,0.00049857155,0.0000022583906,0.00024723407,0.00027571316,0.015710112,0.00008042104,0.0040824823,0.0002725315],"about_ca_topic_score_codex":0.0012759982,"about_ca_topic_score_gemma":0.0005614326,"teacher_disagreement_score":0.06796767,"about_ca_system_score_codex":0.0003916392,"about_ca_system_score_gemma":0.00076158444,"threshold_uncertainty_score":0.575609},"labels":[],"label_agreement":null},{"id":"W4409145217","doi":"10.1016/j.ejcskn.2025.100496","title":"Development of lymphoid aggregates in metastatic uveal melanoma (mUM) tumors treated with tebentafusp","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Metastatic melanoma; Melanoma; Medicine; Lymphatic system; Pathology; Cancer research; Oncology","score_opus":0.009475032897688683,"score_gpt":0.25658775431144637,"score_spread":0.24711272141375767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409145217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96751416,0.031046057,0.000035295965,0.00009344139,0.00017873928,0.00026083336,0.000017813516,0.000028313585,0.00082536595],"genre_scores_gemma":[0.99198294,0.0003878392,0.00038624322,0.000121325334,0.000004084793,0.00014587151,0.00004075722,0.000016893606,0.0069140485],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879956,0.00016728356,0.00042912186,0.0002418768,0.000039491097,0.0003226925],"domain_scores_gemma":[0.99944156,0.00013879602,0.00015012387,0.00021236893,0.000048301623,0.000008849782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018011301,0.00020842129,0.00043305912,0.00027980361,0.00008919759,0.000008161233,0.00019880806,0.00008731959,0.0007906922],"category_scores_gemma":[0.00001829968,0.00015865259,0.00005514728,0.00041312454,0.00018242221,0.00006341866,0.000041092735,0.00013081034,0.00003475384],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00806714,0.0007070551,0.106772035,0.00017216583,0.0023321013,0.00003896245,0.005862983,0.00006755262,0.60778165,0.00044302098,0.0008371099,0.2669182],"study_design_scores_gemma":[0.004027759,0.00012856995,0.06362426,0.0005265453,0.000047486064,0.000029177267,0.0006857114,0.000002500338,0.86797,0.000019688154,0.062728725,0.00020958862],"about_ca_topic_score_codex":0.0011522594,"about_ca_topic_score_gemma":0.0007803551,"teacher_disagreement_score":0.26670864,"about_ca_system_score_codex":0.00018458173,"about_ca_system_score_gemma":0.00062590075,"threshold_uncertainty_score":0.8657526},"labels":[],"label_agreement":null},{"id":"W4414823153","doi":"10.1016/j.ejcskn.2025.100757","title":"Defining melanoma quality indicators: A modified Delphi approach","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; Doug Bragg Enterprises (Canada); Sunnybrook Health Science Centre; University of Toronto; Western University; Health Sciences Centre; McMaster University Medical Centre; Women's College Hospital; Lakeridge Health; University of Ottawa; Oakville Public Library; Mount Sinai Hospital; Princess Margaret Cancer Centre; McMaster University; Queen's University; Cancer Care Ontario","funders":"Ontario Ministry of Health and Long-Term Care; Cancer Care Ontario","keywords":"Delphi method; Likert scale; Delphi; Quality (philosophy); Quality assurance; Melanoma; Mucosal melanoma; Health care","score_opus":0.10227402289945149,"score_gpt":0.4835386961224877,"score_spread":0.3812646732230362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414823153","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15180078,0.0024066975,0.0077531626,0.006468231,0.0005519399,0.0008844202,0.00004128766,0.00050819584,0.82958525],"genre_scores_gemma":[0.9923758,0.00021196941,0.0025038451,0.00046570346,0.00016830268,0.0005633772,0.000005783665,0.000014911421,0.0036903406],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974732,0.00049073447,0.00031660462,0.00041251248,0.0007589964,0.00054798665],"domain_scores_gemma":[0.9988618,0.000416813,0.00010699607,0.00037396917,0.00011136969,0.0001290813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027320278,0.00012973436,0.00023035801,0.0003356315,0.00050523115,0.00012837969,0.00075743627,0.0002295998,0.0003002712],"category_scores_gemma":[0.00069861644,0.00013118563,0.00009324915,0.0015107645,0.0004160808,0.00014104503,0.00018076815,0.0003645492,0.000030598025],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007405045,0.00017675884,0.030641291,0.000095841475,0.00011026125,0.0000073348183,0.017210074,0.00008395451,0.00007457855,0.75643873,0.056897063,0.13819009],"study_design_scores_gemma":[0.0018900146,0.000071584254,0.08926745,0.00040320246,0.00008329791,0.0000015876657,0.028100785,0.0009207593,0.0038216196,0.06135899,0.81266266,0.0014180725],"about_ca_topic_score_codex":0.01955484,"about_ca_topic_score_gemma":0.0025021636,"teacher_disagreement_score":0.840575,"about_ca_system_score_codex":0.0005390473,"about_ca_system_score_gemma":0.0010530162,"threshold_uncertainty_score":0.986974},"labels":[],"label_agreement":null}]}